An Open Label Dose Escalation Study of Intravenous Paricalcitol (ZEMPLAR) [19-NOR-1 ALPHA, 25 - (OH) D] With Zoledronic Acid (Zometa) in Patients With Multiple Myeloma.

Trial Profile

An Open Label Dose Escalation Study of Intravenous Paricalcitol (ZEMPLAR) [19-NOR-1 ALPHA, 25 - (OH) D] With Zoledronic Acid (Zometa) in Patients With Multiple Myeloma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Paricalcitol (Primary) ; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top